Liquidia Co. (NASDAQ: LQDA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $25.00 price target on the stock.
UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder [Yahoo! Finance]
Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder